Janus Kinase Inhibitors: all 1,428 studies that test it
Page 3 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- Tofacitinib in Patients With Amyotrophic Lateral SclerosisNot yet recruitingNCT06689982Early Phase 1
- JAK Inhibitor Dose TAPering Strategy StudyRecruitingNCT06687551Phase 4
- Upadacitinib as a Novel Treatment for Refractory Eyelid DermatitisRecruitingNCT06684522Early Phase 1
- Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host DiseaseRecruitingNCT06682169Phase 3
- Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06675123Phase 1
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesRecruitingNCT06671483Phase 3
- Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative ColitisRecruitingNCT06660693Phase 3
- Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic TherapyRecruitingNCT06660355Phase 2
- Efficacy and Safety of Tofacitinib in Refractory Blau SyndromeEnrolling by invitationNCT06660329Phase 4
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisRecruitingNCT06654882Phase 3
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVIDRecruitingNCT06631287Phase 3
- A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative StudyRecruitingNCT06630091Phase 2
- TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITISNot yet recruitingNCT06625450Phase 4
- Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerRecruitingNCT06616155Phase 1/2
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingNCT06615050Phase 3
- REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2Not yet recruitingNCT06607367Phase 1/2
- A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental VitiligoRecruitingNCT06548360Phase 3
- Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromeRecruitingNCT06538181Phase 1
- Ruxolitinib Treatment in Inclusion Body MyositisRecruitingNCT06536166Phase 2
- Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)RecruitingNCT06527534Phase 4
- Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's DiseaseRecruitingNCT06520397Phase 4
- Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell LymphomaRecruitingNCT06519526Phase 2
- Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisRecruitingNCT06517875Phase 2
- Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaRecruitingNCT06508463Phase 1
- A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's ArteritisRecruitingNCT06498089Phase 4
- A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular AdenomasRecruitingNCT06490757Phase 2
- Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD PatientsNot yet recruitingNCT06465732Phase 4
- Efficacy of Upadacitinib After NECS in VitiligoRecruitingNCT06454461Not applicable
- A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic ArthritisRecruitingNCT06454188Phase 4
- Baricitinib for the Lung Injury Following Spontaneous SAHNot yet recruitingNCT06439615Phase 2
- 3T Therapy in the Treatment of MDA5-positive DermatomyositisEnrolling by invitationNCT06438679Phase 4
- Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedRecruitingNCT06414681Early Phase 1
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingNCT06381661Phase 2
- Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult SubjectsRecruitingNCT06379958Phase 1
- Ritlecitinib in Patients With Keloids or Those Undergoing KeloidectomyRecruitingNCT06373458Phase 2
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingNCT06345495Phase 2
- Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitingNCT06303193Phase 1/2
- Methotrexate Combined With Tofacitinib in Rheumatoid ArthritisRecruitingNCT06301373Not applicable
- A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host DiseaseRecruitingNCT06300320Phase 2
- Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene MutationRecruitingNCT06291987Phase 1
- Drug Rediscovery for Rare Immune Mediated Inflammatory DiseasesRecruitingNCT06285539Phase 2
- JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care UnitNot yet recruitingNCT06244862Phase 2
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaRecruitingNCT06235801Phase 1/2
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT06233461Phase 2
- Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHDRecruitingNCT06233110Phase 1
- A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's DiseaseRecruitingNCT06227910Phase 3
- A Trial of Selinexor, Ruxolitinib and MethylprednisoloneRecruitingNCT06225310Phase 1
- Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological TumorsNot yet recruitingNCT06221774Phase 1/2
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingNCT06218628Phase 1
- Efficacy and Safety of Tofacitinib in Patients With Prurigo NodularisNot yet recruitingNCT06201715Not applicable
- PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of ImmunityRecruitingNCT06199427Phase 2
- Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)RecruitingNCT06160791Phase 2
- Pacritinib in CMMLRecruitingNCT06159491Phase 1/2
- Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeRecruitingNCT06128070Phase 2
- A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)RecruitingNCT06122831Phase 1/2
- Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal NecrolysisRecruitingNCT06119490Early Phase 1
- Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With TofacitinibRecruitingNCT06114407Phase 2
- ToFAcitinib in Early Active Axial SpondyloarThritis:RecruitingNCT06112665Phase 4
- Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative ColitisRecruitingNCT06095596Not applicable
- MAP-guided Preemptive Therapy of aGvHD by RuxolitinibNot yet recruitingNCT06075225Phase 2
- Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/ContusionsRecruitingNCT06065046Phase 2
- Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)RecruitingNCT06052618Phase 2
- Effectiveness of Tofacitinib in Systemic SclerosisRecruitingNCT06044844Phase 2
- A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsRecruitingNCT06034002Phase 1
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataRecruitingNCT06012240Phase 3
- Tofacitinib Associated With Meglumine Antimoniate in Cutaneous LeishmaniasisNot yet recruitingNCT06011343Phase 2/3
- Neratinib in Combination With Ruxolitinib in Patients With mTNBCRecruitingNCT06008275Early Phase 1
- Go-CHOP as the Frontline Therapy for PTCLRecruitingNCT05963347Phase 2
- Effect of JAK Inhibitor on Erosion Healing in RARecruitingNCT05955066Phase 4
- Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune ThrombocytopeniaRecruitingNCT05932524Phase 2
- Ruxolitinib as GVHD Prophylaxis in AA PatientsNot yet recruitingNCT05914714Phase 2
- "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.Not yet recruitingNCT05914584Phase 2/3
- Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell LymphomaNot yet recruitingNCT05900089Phase 1
- Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVRecruitingNCT05870475Phase 2
- Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative ColitisRecruitingNCT05867329Phase 4
- Correction of Psoriatic T Cell Signatures by DeucravacitinibRecruitingNCT05858645Phase 4
- Inflammation and Depression in People With HIVRecruitingNCT05849038Phase 2
- Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's SyndromeRecruitingNCT05845723Phase 2
- Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPNRecruitingNCT05817955Phase 2
- Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RDRecruitingNCT05781516Not applicable
- Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)RecruitingNCT05762640Phase 2
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingNCT05757219Phase 2
- Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's ArteritisRecruitingNCT05749666Phase 3
- HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05745714Phase 1/2
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataRecruitingNCT05723198Phase 3
- A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisRecruitingNCT05714072Phase 1
- Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior UveitisNot yet recruitingNCT05651880Phase 3
- Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.RecruitingNCT05609630Phase 3
- Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT ModelRecruitingNCT05599256Phase 2
- Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic LeukemiaRecruitingNCT05592015Phase 2
- Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)RecruitingNCT05531786Phase 1/2
- Immunoclassification of Psoriasis: a Strategy for Precision MedicineRecruitingNCT05503875Not applicable
- Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid ArthritisNot yet recruitingNCT05502731Phase 4
- Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic LymphohistiocytosisRecruitingNCT05491304Phase 4
- Baricitinib for Reduction of HIV - CNSRecruitingNCT05452564Phase 2
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataRecruitingNCT05398809Phase 2
- Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
- Stand UP to Rheumatoid Arthritis (SUPRA)RecruitingNCT05305066Not applicable
- Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibRecruitingNCT05280509Phase 1/2
- A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative ColitisRecruitingNCT05181137Phase 3